top of page
The Sound of Evolution
Ixazomib
Mechanism of action:
Ixazomib is a proteasome inhibitor. It reversibly inhibits the β5 subunit of the 26S proteasome, leading to the accumulation of misfolded proteins, triggering endoplasmic reticulum stress (ER stress), causing cell cycle arrest in the G₂-M phase, and inducing apoptosis.
Reference(s):
1. Offidani M et al. (2014). An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther.
2. Raedler LA et al. (2016). Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma. Am Health Drug Benefits.
3. Shirley M et al. (2016). Ixazomib: first global approval. Drugs.
bottom of page